Astria Therapeutics, Inc.
ATXS
$5.17
-$0.04-0.77%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.66M | 8.50M | 8.09M | 8.52M | 7.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.59M | 29.01M | 28.80M | 24.15M | 19.00M |
| Operating Income | -29.59M | -29.01M | -28.80M | -24.15M | -19.00M |
| Income Before Tax | -25.63M | -24.53M | -24.17M | -19.93M | -31.41M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.63M | -24.53M | -24.17M | -19.93M | -31.41M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.63M | -24.53M | -24.17M | -19.93M | -31.41M |
| EBIT | -29.59M | -29.01M | -28.80M | -24.15M | -19.00M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.44 | -0.42 | -0.43 | -0.38 | -0.86 |
| Normalized Basic EPS | -0.28 | -0.27 | -0.27 | -0.24 | -0.28 |
| EPS Diluted | -0.44 | -0.42 | -0.43 | -0.38 | -0.86 |
| Normalized Diluted EPS | -0.28 | -0.27 | -0.27 | -0.24 | -0.28 |
| Average Basic Shares Outstanding | 58.02M | 57.82M | 56.49M | 52.29M | 36.49M |
| Average Diluted Shares Outstanding | 58.02M | 57.82M | 56.49M | 52.29M | 36.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |